SpecialtiesQuestion

How does your treatment for 1L mHSPC change if a patient has somatic RAD51D mutation?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?

What would you offer for a very young patient with metastatic renal medullary carcinoma who has progressed on cisplatin-based chemotherapy?

What are the treatment options for a patient with unfavorable intermediate risk PCa who desires future child bearing?

Does the results of a PSMA scan affect the decision to start docetaxel chemotherapy in castrate sensitive metastatic prostate cancer?

Is the PROTEUS data enough to change your practice in the treatment of patients with high-risk localized or locally advanced prostate cancer?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.